Add Glucokinase Activator to Target A1c
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.
Also called NCT02405260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 190 participants
- Sponsor
- Registry
-
NCT02405260
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02405260. Randomized; double masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2016-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Add Glucokinase Activator to Target A1c
- Acronym
- AGATA
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- TTP399 400 mg
- Intervention (Drug)
- TTP399 800 mg
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- vTv Therapeutics
Record details
- Record id
cardio:ct-nct02405260- Content hash
9f4b1202b80f5b5506c287dc099ee69801031eb3ed6a7ce11701617d7fcd6f05